New depression drug shows promise in Mid-Stage trial
NCT ID NCT06842992
First seen Jan 08, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This study tested a new medicine, NH102, for people with major depression. 243 adults took part to see if it helps reduce depression symptoms compared to a placebo or an existing drug (duloxetine). The goal is to find the right dose and check safety before moving to larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Mental Health Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.